Meeting
2013 ASCO Annual Meeting
CYP3A4 phenotyping with midazolam to predict sunitinib exposure.
Authors
Nielka P van Erp
Department of Clinical Pharmacy, University Medical Centre Radboud, Nijmegen, Netherlands
Nielka P van Erp , Djoeke de Wit , Alex Sparreboom , Jan den Hartigh , Margret den Hollander , Jacqueline M.C. Konig-Quartel , Trees Hessing , Henk-jan Guchelaar , Hans Gelderblom
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
Pharmacology
Clinical Trial Registration Number
NCT01743300
Citation
J Clin Oncol 31, 2013 (suppl; abstr 2592)
DOI
10.1200/jco.2013.31.15_suppl.2592
Abstract #
2592
Poster Bd #
8D
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
The utility of genomics and functional imaging to predict Sunitinib PK and PD: The Predict SU study.
First Author: Michael Michael
Poster
2018 ASCO Annual Meeting
Impact of curcumin with and without (+/-) piperine on tamoxifen exposure.
First Author: Gerardus Hussaarts
Poster
2013 ASCO Annual Meeting
Association analysis of polymorphisms in genes related to sunitinib pharmacokinetics.
First Author: Meta Diekstra
Poster
2024 ASCO Annual Meeting
Peak study: A phase 3, randomized, open-label multi-center clinical study of bezuclastinib (CGT9486) and sunitinib combination versus sunitinib in patients with gastrointestinal stromal tumors (GIST).
First Author: William D. Tap